The Journal of Immunology, Vol 151, Issue 10 5726-5741, Copyright © 1993 by American Association of Immunologists

ARTICLES

Murine recipients of fully mismatched donor marrow are protected from lethal graft-versus-host disease by the in vivo administration of rapamycin but develop an autoimmune-like syndrome

BR Blazar, PA Taylor, DC Snover, SN Sehgal and DA Vallera
Department of Pediatrics, University of Minnesota Hospital and Clinic, Minneapolis 55455.

We investigated the ability of the macrolide antifungal agent rapamycin (RAPA) to inhibit murine graft-vs-host disease induced across the MHC barrier. An optimum dose (1.5 mg/kg) given for 14 days beginning on the day of transplant (and then three times weekly until 1 mo) effectively and significantly (p < 0.001) protected 80% of irradiated B10.BR recipients of C57Bl/6 bone marrow/spleen grafts for over 90 days, whereas 80% of control mice died by day 37. Using a congenic model in which a mixture of Ly5.1+ bone marrow (T cell-depleted) and Ly5.2+ spleen cells allowed us to distinguish mature and immature cells, we found that RAPA inhibits the splenic expansion of mature donor-derived T cells in B10.BR recipients after bone marrow transplantation. In addition, phenotyping studies revealed that RAPA causes a massive reduction of immature CD4+CD8+ T cells in the thymus, indicating that RAPA probably interferes with maturation of immature CD3-CD4-CD8- T cells to CD4+CD8+ T cells. There was also a predilection toward development or intrathymic retention of the more mature CD3+CD4-CD8+ or CD3+CD4+CD8- cells in the thymus of long term survivors. These same observations were made in different experiments with mice given syngeneic bone marrow transplantation and RAPA. However, RAPA administration was associated with the occurrence of an autoimmune-like syndrome, consisting of ulcerative dermatitis, hepatic bile duct proliferation, and nondestructive lymphoid peribronchiolar infiltration of the lung. RAPA interfered with the deletion of potentially self- reactive T cells that occurs in thymic development. The failure of clonal deletion was observed in allogeneic and syngeneic transplants given RAPA, although only the allografted mice experienced an autoimmune-like syndrome. Some, but not all, of the nondeleted V beta populations were functionally active. These new findings bear certain dissimilarities to the syndrome and lesions observed with cyclosporin A treatment, particularly in the observation of bile duct proliferation and ulcerative skin lesions. Nonetheless, because of the potent effect of RAPA in preventing lethal graft-vs-host induced across the MHC, further investigation of the immune consequences of this highly effective compound is warranted.

This article has been cited by other articles:

				C. Wei, C. I. Amos, N. Zhang, X. Wang, A. Rashid, C. L. Walker, R. R. Behringer, and M. L. Frazier Suppression of Peutz-Jeghers Polyposis by Targeting Mammalian Target of Rapamycin Signaling Clin. Cancer Res., February 15, 2008; 14(4): 1167 - 1171. [Abstract] [Full Text] [PDF]

				R. Zeiser, V. H. Nguyen, A. Beilhack, M. Buess, S. Schulz, J. Baker, C. H. Contag, and R. S. Negrin Inhibition of CD4+CD25+ regulatory T-cell function by calcineurin-dependent interleukin-2 production Blood, July 1, 2006; 108(1): 390 - 399. [Abstract] [Full Text] [PDF]

				J.-K. Chen, J. Chen, E. G. Neilson, and R. C. Harris Role of Mammalian Target of Rapamycin Signaling in Compensatory Renal Hypertrophy J. Am. Soc. Nephrol., May 1, 2005; 16(5): 1384 - 1391. [Abstract] [Full Text] [PDF]

				M. H. Albert, X.-Z. Yu, P. J. Martin, and C. Anasetti Prevention of lethal acute GVHD with an agonistic CD28 antibody and rapamycin Blood, February 1, 2005; 105(3): 1355 - 1361. [Abstract] [Full Text] [PDF]

				T. Shioi, J. R. McMullen, O. Tarnavski, K. Converso, M. C. Sherwood, W. J. Manning, and S. Izumo Rapamycin Attenuates Load-Induced Cardiac Hypertrophy in Mice Circulation, April 1, 2003; 107(12): 1664 - 1670. [Abstract] [Full Text] [PDF]

				P. A. Taylor, C. J. Lees, J. M. Wilson, M. J. Ehrhardt, M. T. Campbell, R. J. Noelle, and B. R. Blazar Combined effects of calcineurin inhibitors or sirolimus with anti-CD40L mAb on alloengraftment under nonmyeloablative conditions Blood, October 16, 2002; 100(9): 3400 - 3407. [Abstract] [Full Text] [PDF]

				T. Shioi, J. R. McMullen, P. M. Kang, P. S. Douglas, T. Obata, T. F. Franke, L. C. Cantley, and S. Izumo Akt/Protein Kinase B Promotes Organ Growth in Transgenic Mice Mol. Cell. Biol., April 15, 2002; 22(8): 2799 - 2809. [Abstract] [Full Text] [PDF]

				J. D.K. Wilson, G. S. Ogg, R. L. Allen, P. J.R. Goulder, A. Kelleher, A. K. Sewell, C. A. O'Callaghan, S. L. Rowland-Jones, M. F.C. Callan, and A. J. McMichael Oligoclonal Expansions of CD8+ T Cells in Chronic HIV Infection Are Antigen Specific J. Exp. Med., August 17, 1998; 188(4): 785 - 790. [Abstract] [Full Text] [PDF]

				B. R. Blazar, P. A. Taylor, A. Panoskaltsis-Mortari, and D. A. Vallera Rapamycin Inhibits the Generation of Graft-Versus-Host Disease- and Graft-Versus-Leukemia-Causing T Cells by Interfering with the Production of Th1 or Th1 Cytotoxic Cytokines J. Immunol., June 1, 1998; 160(11): 5355 - 5365. [Abstract] [Full Text] [PDF]

				G. R. Hill, J. M. Crawford, K. R. Cooke, Y. S. Brinson, L. Pan, and J. L.M. Ferrara Total Body Irradiation and Acute Graft-Versus-Host Disease: The Role of Gastrointestinal Damage and Inflammatory Cytokines Blood, October 15, 1997; 90(8): 3204 - 3213. [Abstract] [Full Text] [PDF]